Search

The Pathogens, Immunity and Inflammation Hub is pleased to bring back the “ On the Cross-Road of Immunology and Women’s Health Seminar Series” this fall and throughout the academic year! This series will feature talks and panel discussions by BIDMC experts about: Immunologic conditions more common...

The Neuroscience Connections Hub hosts Directors of the BIDMC Research Core Facilities the first Monday of every month to present about the capabilities in their Research Core On November 4 th from 12-1 pm in CLS 621, Dr. Jennifer Stevens, the Director of the Center for Healthcare Delivery Science...

The Pathogens, Immunity and Inflammation Translational Research Hub has been hosting a new three-part course titled How to Win Industry Funding: Industry-Sponsored Research Funding 101. The first part of this course, Introduction to Industry-Sponsored Research Funding was held June 22, 2023, and the...

Donec eu sapien Morbi ac sem eget diam facilisis lobortis. Donec eu sapien maximus, sollicitudin dolor ut, semper urna. Fusce nec accumsan mauris. Integer semper, justo vitae luctus auctor, mi enim maximus sapien, eu dignissim ligula est id felis. Mauris varius arcu ex, eget mollis est pulvinar ut...

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse...

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse...

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse...

Congratulation to Dr. Ben Freedman and team on their publication in Nature Biomedical Engineering! Check out the article here.

Key takeaways: Eighty-three percent of patients maintained virologic suppression after the bNAb cocktail for 28 weeks. Forty-two percent had virologic suppression for 38 to 44 weeks despite the decline of bNAb concentrations.

Phase 1 study is among first to examine mRNA technology for HIV.